NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Indivior Pharmaceuticals, Inc. INDV
4 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.2B
▲ 4.3% vs FY2024
EPS · FY25
$1.64
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
16.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.2B
Revenue, FY2025 · full 4-year series below
Revenue
Net income
17 cents of every revenue dollar became profit this year.
Per share
USD 1.64
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin21.1%
Net margin16.9%
Return on assets16.7%
Returned to shareholders
USD 9.0M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 9.0M
Share of profit4.3%
Consecutive raises—
USD 9.0M in buybacks — 4% of the year's profit went back to shareholders.
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+11.2%
Returned to shareholders
−53.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.2B
total assets, end of FY2025
Total assetsUSD 1.2B
EquityUSD -98.0M
CashUSD 195.0M
Gross debtUSD 319.0M
Net debtUSD 124.0M
Current ratio0.71×
Net debt stands at -127% of equity.
History
4 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
Revenue $B
1.2
1.2
1.1
0.9
Operating income $B
0.3
0.0
−0.2
−0.1
EBITDA $B
0.3
0.1
−0.1
−0.1
Income tax $B
0.0
0.0
−0.0
−0.0
Net income $B
0.2
0.0
−0.1
−0.0
EPS, diluted $
1.64
0.05
−0.92
−0.32
Dividend / sh $
·
·
·
·
Payout %
·
·
·
·
ROE %
·
·
·
·
Shares out B
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
14 of 14
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed